19 hours Ago By Defense World Staff
KLP Kapitalforvaltning AS acquired a new position in Amedisys, Inc. ( NASDAQ:AMED – Free Report ) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 6,500 shares of the health services provider’s stock, valued at approximately $590,000.
Several other institutional investors have also recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. boosted its position in shares of Amedisys by 2.
7% in the third quarter. Charles Schwab Investment Management Inc. now owns 346,082 shares of the health services provider’s stock worth $33,400,000 after purchasing an additional 9,004 shares during the period.
Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Amedisys by 15.4% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,781 shares of the health services provider’s stock valued at $654,000 after buying an additional 903 shares in the last quarter.
Holocene Advisors LP lifted its stake in shares of Amedisys by 391.4% during the 3rd quarter. Holocene Advisors LP now owns 79,036 shares of the health services provider’s stock valued at $7,628,000 after buying an additional 62,953 shares in the last quarter.
Polar Asset Management Partners Inc. bought a new position in Amedisys in the 3rd quarter worth $28,953,000. Finally, Point72 DIFC Ltd purchased a new stake in Amedisys in the 3rd quarter worth $371,000.
Institutional investors own 94.36% of the company’s stock. Analyst Ratings Changes Separately, Stephens restated an “equal weight” rating and issued a $101.
00 price objective on shares of Amedisys in a research report on Tuesday, March 4th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, Amedisys presently has a consensus rating of “Hold” and an average price target of $101.
00. Amedisys Price Performance Shares of NASDAQ:AMED opened at $92.98 on Thursday.
The firm has a market cap of $3.05 billion, a price-to-earnings ratio of 36.90, a P/E/G ratio of 1.
78 and a beta of 0.76. The firm has a fifty day moving average price of $92.
32 and a 200 day moving average price of $92.35. Amedisys, Inc.
has a fifty-two week low of $82.15 and a fifty-two week high of $98.95.
The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.
19. Amedisys ( NASDAQ:AMED – Get Free Report ) last released its quarterly earnings data on Wednesday, February 26th. The health services provider reported $0.
96 EPS for the quarter, missing the consensus estimate of $1.05 by ($0.09).
The company had revenue of $598.05 million for the quarter, compared to the consensus estimate of $602.38 million.
Amedisys had a net margin of 3.57% and a return on equity of 12.20%.
As a group, sell-side analysts expect that Amedisys, Inc. will post 4.4 earnings per share for the current fiscal year.
Amedisys Profile ( Free Report ) Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
See Also Five stocks we like better than Amedisys 3 Grocery Stocks That Can Help Take a Bite Out of Inflation Homebuilders in Freefall: Bargain Opportunity or Falling Knife? Market Cap Calculator: How to Calculate Market Cap The 3 Most Talked About Investments on WallStreetBets Right Now Ride Out The Recession With These Dividend Kings Analyst Targets Signal More Growth in CrowdStrike Stock Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter ..
